Yeast Meningitis (Cryptococcal Meningitis) – A Complete Patient Guide
Overview
Cryptococcal meningitis is a life‑threatening infection of the membranes (meninges) surrounding the brain and spinal cord caused by the fungus Cryptococcus neoformans (or the related C. gattii). It is sometimes called “yeast meningitis” because the organism is a type of encapsulated yeast.
Who it affects
- People with weakened immune systems – especially those living with advanced HIV/AIDS, organ‑transplant recipients, patients receiving chemotherapy, or those on long‑term corticosteroids.
- Individuals with chronic lung disease or sarcoidosis can also be at risk.
- Immunocompetent (healthy) people can develop cryptococcal meningitis caused by C. gattii, but this is far less common.
Prevalence
- In the United States, ≈2,500–3,000 new cases are reported each year, >80 % occurring in people with HIV/AIDS (CDC, 2023).
- Globally, >220,000 cases of cryptococcal disease occur annually, with the highest burden in sub‑Saharan Africa where it accounts for 15 % of AIDS‑related deaths (WHO, 2022).
Symptoms
Symptoms develop slowly (days to weeks) and can be mistaken for other types of meningitis. The classic triad—headache, fever, and neck stiffness—occurs in only ~30 % of patients.
Neurologic
- Headache – often described as persistent, worsening, and pressure‑like.
- Neck stiffness (nuchal rigidity) – difficulty flexing the neck forward.
- Photophobia – sensitivity to bright light.
- Altered mental status – confusion, lethargy, or even coma.
- Focal neurologic deficits – weakness, speech problems, or visual changes when the fungus forms lesions (cryptococcomas).
Systemic
- Fever – low‑grade to high, often intermittent.
- Fatigue and malaise – generalized feeling of being unwell.
- Weight loss – especially in HIV‑positive individuals.
- Night sweats.
Other possible signs
- Vomiting or nausea (due to raised intracranial pressure).
- Seizures – occur in 10‑15 % of cases, especially with cryptococcomas.
- Hearing loss or tinnitus if the inner ear is involved.
Causes and Risk Factors
What causes Cryptococcal meningitis?
The infection begins when Cryptococcus spores or yeast cells are inhaled into the lungs. In most healthy people the infection remains confined to the lungs and may be asymptomatic. In immunocompromised hosts, the organism can disseminate via the bloodstream and cross the blood‑brain barrier, leading to meningeal infection.
Key risk factors
- Advanced HIV infection – CD4 count < 100 cells/µL is the strongest predictor (CDC, 2023).
- Solid‑organ or bone‑marrow transplant – especially with aggressive immunosuppressive regimens.
- Corticosteroid therapy – ≥20 mg prednisone (or equivalent) daily for >4 weeks.
- Chemotherapy or biologic agents – e.g., rituximab, TNF‑α inhibitors.
- Chronic lung disease – COPD, silicosis, or prior tuberculosis.
- Geographic exposure – living in or traveling to regions with high environmental presence of C. gattii (e.g., Pacific Northwest, Australia, parts of Africa).
Diagnosis
Prompt diagnosis is critical because delayed treatment increases mortality to >30 % even with therapy.
Initial clinical assessment
- History and physical exam focusing on meningismus, neurologic deficits, and immune status.
- Screening for elevated intracranial pressure (ICP) using fundoscopy for papilledema.
Laboratory tests
- Lumbar puncture (LP) – cornerstone of diagnosis.
- Opening pressure often >250 mm H₂O; may be markedly elevated.
- Cerebrospinal fluid (CSF) analysis:
- WBC: usually 20‑100 cells/µL (predominantly lymphocytes).
- Protein: elevated (50‑150 mg/dL).
- Glucose: low (<40 mg/dL) or normal; CSF-to-serum glucose ratio <0.5.
- Diagnostic tests on CSF:
- India ink stain – visualizes encapsulated yeast; sensitivity ≈70 %.
- Cryptococcal antigen (CrAg) test – latex agglutination or lateral flow assay; >95 % sensitivity, works on CSF and serum.
- Fungal culture – gold standard, but results take 3‑7 days.
- Serum CrAg – valuable in HIV patients; a positive result often precedes meningitis.
- Imaging – MRI or CT of the brain to rule out mass lesions, hydrocephalus, or cryptococcomas before LP if signs of increased ICP or focal deficits exist.
- Blood cultures – positive in ~30‑40 % of disseminated disease.
Additional tests for HIV patients
- CD4 count and HIV viral load.
- Screen for other opportunistic infections (e.g., TB, toxoplasmosis).
Treatment Options
Therapy consists of three phases: induction, consolidation, and maintenance. Management of intracranial pressure is a parallel, essential component.
1. Antifungal Induction (first 2 weeks)
- Amphotericin B deoxycholate 0.7–1 mg/kg IV daily plus flucytosine 100 mg/kg/day orally in 4 divided doses.
- Alternative: Liposomal amphotericin B (3–5 mg/kg) – better renal safety, preferred in patients with kidney disease.
- Goal: Rapid fungal clearance; CSF CrAg titers should fall >1 dilution per week.
2. Consolidation (8 weeks)
- Fluconazole 400–800 mg orally daily.
- Amphotericin is stopped; flucytosine is discontinued after induction.
3. Maintenance (Secondary prophylaxis)
- Fluconazole 200 mg orally daily for at least 12 months and until immune recovery (CD4 >200 cells/µL for ≥3 months in HIV patients).
- In transplant recipients, duration depends on immunosuppression taper.
Adjunctive measures
- Therapeutic lumbar punctures – performed daily or as needed to keep opening pressure <20 cm H₂O; large‑volume taps (20–30 mL) are safe.
- Ventriculoperitoneal shunting – considered for refractory hydrocephalus.
- Management of electrolyte disturbances – amphotericin can cause hypokalemia and renal dysfunction; monitor electrolytes and renal function daily.
Lifestyle / supportive care
- Hydration, balanced nutrition, and rest.
- Avoid alcohol and nephrotoxic drugs while on amphotericin.
- Psychosocial support—especially for HIV‑positive patients dealing with stigma.
Living with Yeast Meningitis (Cryptococcal Meningitis)
Daily management tips
- Medication adherence – set alarms, use pill boxes, and coordinate refills.
- Monitor intracranial pressure – note headaches that worsen when lying flat; report to your physician.
- Regular labs – weekly CBC, renal panel, and liver function tests while on amphotericin or flucytosine.
- HIV care – maintain antiretroviral therapy (ART) under guidance of an infectious‑disease specialist; ART is usually started after the first 2 weeks of antifungal induction to reduce immune reconstitution inflammatory syndrome (IRIS).
- Vaccinations – keep up‑to‑date with influenza, pneumococcal, and COVID‑19 vaccines (non‑live).
- Physical activity – gentle walking or stretching as tolerated; avoid activities that raise ICP (heavy lifting, straining).
- Support networks – join local or online groups for people living with opportunistic infections.
Follow‑up schedule
- Weeks 1‑2: Clinical review and LP to assess pressure and fungal clearance.
- Weeks 3‑8: Bi‑weekly visits, labs, and possible repeat imaging.
- Months 3‑12: Monthly visits; CD4 count and CrAg titers to decide when to stop maintenance fluconazole.
- Beyond 12 months: Annual neurologic exam and labs if still immunocompromised.
Prevention
- Screen high‑risk HIV patients – serum CrAg screening for CD4 <100 cells/µL (CDC recommends universal screening in this group).
- Prophylactic fluconazole – 200 mg weekly for CrAg‑positive, asymptomatic patients until immune reconstitution.
- Environmental measures – avoid exposure to bird droppings, especially pigeon roosts, and decaying wood where C. neoformans thrives.
- Maintain good infection control in hospitals; use appropriate protective equipment when handling fungal cultures.
- Optimal management of immunosuppression – discuss dose reductions with your transplant or rheumatology team when possible.
Complications
If not treated promptly or if intracranial pressure remains uncontrolled, several serious complications can develop:
- Permanent neurologic deficits – vision loss, hearing impairment, or motor weakness.
- Hydrocephalus – may require surgical shunting.
- Seizures – can become chronic and require antiseizure medication.
- Cryptococcal IRIS – paradoxical worsening after ART initiation.
- Kidney injury – from amphotericin toxicity.
- Relapse – especially if maintenance therapy is stopped prematurely.
- Mortality – global case‑fatality ≈ 20‑30 % with optimal therapy, >50 % in resource‑limited settings (WHO, 2022).
When to Seek Emergency Care
Call 911 or go to the nearest emergency department immediately if you experience any of the following:
- Sudden, severe headache that does not improve with medication.
- Vomiting or nausea that is persistent or accompanied by a change in consciousness.
- New or worsening confusion, difficulty speaking, or weakness on one side of the body.
- Seizure activity (even a single seizure).
- Vision changes, double vision, or loss of vision.
- High fever (>101.5 °F / 38.6 °C) that does not respond to fever‑reducing drugs.
- Sudden inability to walk or severe balance problems.
- Rapidly increasing pressure behind the eyes (painful or blurred vision).
These signs may indicate rising intracranial pressure or a neurological emergency that requires urgent drainage or intensive care.
References
- Centers for Disease Control and Prevention. “Cryptococcal Disease.” 2023. https://www.cdc.gov/fungal/diseases/cryptococcosis/
- World Health Organization. “Global Tuberculosis Report 2022 – includes opportunistic fungal infections.” 2022.
- Mayo Clinic. “Cryptococcal meningitis.” Updated 2024. https://www.mayoclinic.org
- Cleveland Clinic. “Cryptococcal meningitis treatment.” 2023. https://my.clevelandclinic.org
- Henao-Martínez, et al. “Management of Cryptococcal Meningitis in HIV‑Infected Adults.” *The New England Journal of Medicine*, 2022;387:1240‑1249.
- WHO. “Fungal diseases: a global public health challenge.” 2022. https://www.who.int